Puretech Health hails US approval of weight loss aid Plenity
Plenity has been cleared for the BMI 25-40 kg/M2 category, the widest category of adults suffering from obesity
Company
PureTech Health
LON:PRTC
PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others.
44 stories · page 2 of 3
PureTech Health affiliate inks major deal with Japanese pharma
The partnership with Shionogi is worth US$20mln upfront and US$105mln in potential milestone payments
Peel Hunt spotlights 29 stocks with potential to double on 2-3 year view including Base Resources, Eland O&G, Motif Bio, Circassia
The City broker’s analysts pointed out that December is often a time for winding down and celebrating but with the FTSE All Share looking set to record its worst annual performance since 2008 the festive spirit is a little short this year
PureTech Health surges as it hooks up with Swiss drugs giant Roche
PureTech Health has been advancing internal R&D projects that focus on the brain-immune-gut axis, with an emphasis on lymphatics and immune cell trafficking to modulate immunity in a tissue-specific manner.
Investments and investor services
Urals Energy shares lifted as it secures price for latest oil shipment
A look at some of the biggest risers and fallers in London on Friday
PureTech’s 35% stake in resTORbio now worth US$147mln as biopharma floats on Nasdaq
PureTech spent US$22.5mln building up a 35% stake in resTORbio, an interest which is now worth US$147mln
PureTech Health affiliate resTORbio raises another US$40mln as age-related trial progresses
The funding brings equity investment in resTORbio so far this year to US$65mln
World-leading journal flags up the importance of the gut microbiome; makes PureTech affiliate's deal look savvy
On Tuesday PureTech said affiliate Vedanta Biosciences had in-licensed microbiome-derived cancer immunotherapies based on live biotherapeutics
Investments and investor services
FTSE 100 closes higher as traders enjoy 'quiet in the storm'
London's FTSE 100 was trading steadily in Wednesday afternoon's exchanges.
Archive
WH Smith update could make good reading as the count-down to the end of summer continues
The day ahead includes a trading update from books to stationary retailer WH Smith, and results from HSS Hire PLC and Petrofac Limited ...
Archive
Final week of August lull to bring US jobs data, results from the likes of Bunzl and Hays
The week ahead includes results from Bunzl PLC, Hays, PLC, Ladbrokes Coral PLC, a trading update from WH Smith PLC, and the September US jobs report
FTSE 100 finishes lower as Fed's easy money set to end
The index of blue-chip shares succumbed to selling pressure
Gulf Keystone investors will be hoping the worst is over
Last year was extremely dilutive for GKP shareholders, they'll be hoping that 2017 will be better.
Archive
ASOS tipped to show strength
Week ahead: Asos, Panmure Gordon, Sprue Aegis, Electrocomponents
Sirius Minerals named among the ‘top tips’ for 2017
Here we take a look at the medium and small cap companies included among Fleet Street's top stock market tips for 2017.
Investments and investor services
Redrow all the rage with brokers after results
Housebuilder reported a 23% rise in profits to a record £250mln
Preview: Centralnic unlikely to spring any surprises
Internet domain name firm set to stay with consensus numbers
PREVIEW: Will Dechra Pharmaceuticals live up to heightened expectations?
Dechra Pharmaceuticals, housebuilders Berkeley and Barratt, Halfords, Dixons Carphone, and JD Whetherspoon are on the agenda.